The US Food and Drug Administration conducted a cGMP inspection at a facility belonging to Cipla.
2 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The US Food and Drug Administration conducted a cGMP inspection at a facility belonging to Cipla.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
United States Food and Drug Administration
agency of the US Department of Health and Human Services
-
Cipla
Indian multi-national pharmaceutical and biotechnology company
Nothing else this week.
Related events
- The US Food and Drug Administration conducted a routine cGMP inspection of a facility belonging to OneSource Specialty Pharma Limited.
- Routine cGMP inspection found three observations at a Strides Pharma Science Limited manufacturing facility in Chennai.
- The US Food and Drug Administration inspected a plant located in Raleigh, North Carolina.